As Fierce Biotech reports via IMS data, te US drug market shrunk by 1% in 2012. This is the first time that has ever happened. This is due, of course, to the much talked about patent cliff arriving in a big way -- mpacting market share and revenues of some of the world's top selling small molecules. The US market is now down to $325.8 B.
Patent cliff drugs took a $29.8 B dollar hit. Yes, with a Big B. Branded producers in general saw revenues decline by $11.8 B. Generics producers of course saw he upside of things as their sales increased by $8 B. A drug market Yin and Yang as it were. Generics now account for 84% of all drugs prescriptions dispensed in the US.
The bright side for branded manufacturers are for their new drugs (< 24 months old). These actually grew by $0.5 B to a total of $10.8 B. These all fell into the specialty category with drugs like - Incivek (hep C), Eylea (macular degeneration), Xgeva (bone drug), Gilenya (MS), and Yervoy (melanoma). At least the FDA is on an upward trend with approvals, so there may be hope for a continued flow of more new drugs to bolster brand name revenues.
However, the next wave over the patent cliff is also still coming. Here's a report from the end of last year in Fierce Biotech that outlines the next 15 top sellers to go off patent this year.
Posted by Bruce Lehr May 9th 2013.